Novavax, Inc. is a late-stage biotechnology company that creates next-generation vaccines for severe infectious diseases, and contributes to global public health. Listed on the NASDAQ exchange under the ticker symbol NVAX, Novavax first came to prominence for leading the fight against coronavirus disease 2019 (COVID-19) with its vaccine candidate, NVX-CoV2373.
Headquartered in Gaithersburg, Maryland, Novavax was founded in 1987 and has remained committed to using its proprietary recombinant nanoparticle vaccine technology to replicate antigens derived from the virus. This technique is used to develop vaccines that can target a wide array of infectious diseases including COVID-19, seasonal influenza, and respiratory syncytial virus (RSV).
NVX-CoV2373 is the flagship COVID-19 vaccine candidate of Novavax. It is a protein-based vaccine engineered from the genetic sequence of the SARS-CoV-2 virus. This vaccine has been designed to generate enhanced immune responses and to generalise a high level of efficacy. As of late 2021, the vaccine is undergoing Phase 3 clinical trials in locations around the globe.
Moreover, Novavax is also recognized for its potency against influenza with its NanoFlu, a recombinant, quadrivalent, nanoparticle flu vaccine. In 2020, the US Food and Drug Administration (FDA) granted NanoFlu a fast-track designation, thereby accelerating its path to regulatory approval.
Behind its solid scientific and operational development, there lies Novavax's commitment to global health. The company is a member of the Coalition for Epidemic Preparedness Innovations (CEPI), and also works in collaboration with international organizations such as the Bill & Melinda Gates Foundation to ensure affordable and equitable access to vaccines to people all around the world.
Financially, the company has experienced a significant surge in its stock price on the back of its successful advances in vaccine development. However, it has also faced numerous challenges and criticisms, particularly towards its ability to scale up manufacturing.
In the future, Novavax aims to push the boundaries of vaccine science and deliver on promises of creating an enhanced global health landscape. Its core focus extends beyond its current products to involve substantial investment in research and development, with the mission of discovering, testing, and bringing to market more novel vaccines for the betterment of humanity.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Novavax (NVAX) recently closed up 1.1% at $10.11, outperforming the S&P 500 and the Medical sector, despite broader market fluctuations. The company's upcoming earnings are anticipated to show a 40.32% increase in EPS, though quarterly revenue is projected to decline. Analysts' consensus estimates for the full year suggest decreases in both EPS and revenue compared to the previous year, with Novavax currently holding a Zacks Rank of #3 (Hold).
This article analyzes Novavax Inc. (NASDAQ: NVAX), highlighting weak near-term sentiment that could precede shifts in mid and long-term outlook. It presents three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—alongside multi-timeframe signal analysis, showing strong mid- and long-term signals despite near-term weakness.
Novavax Inc. (NASDAQ: NVAX) shows strong sentiment across all time horizons, supporting an overweight bias. AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis highlights a mid-channel oscillation pattern and an exceptional 59.3:1 risk-reward short setup.
Novavax (NASDAQ: NVAX) reported Q2 revenue of $56.7 million, surpassing Wall Street expectations, and raised its full-year 2026 revenue guidance to a range of $235 million-$275 million. The company's shares rose 7% following the announcement, reflecting improved operational efficiency and strong demand visibility. Novavax also highlighted its cash position of $724 million and the potential for a $125 million milestone payment from its Sanofi partnership upon the initiation of a Phase 3 COVID-19-Influenza Combination trial.
Novavax Inc. (NVAX) saw its stock rally 6.55% to $9.44, outperforming major indices like the NASDAQ Composite and the Dow Jones Industrial Average on a strong trading day. The company's stock closed 21.14% below its 52-week high of $11.97, which was reached on February 26th. This performance occurred as the broader market also experienced gains.
Novavax Inc. (NVAX) saw its stock price rally by 6.18% to $8.94, outperforming competitors on a positive trading day for the overall stock market. The company's shares closed 25.31% below its 52-week high of $11.97. This strong performance occurred as both the NASDAQ Composite Index and the Dow Jones Industrial Average also rose.